drugset / Trial / NCT06205628
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
Phase 1
Active not recruiting
28 enrolled
ADARx Pharmaceuticals, Inc.
ADARx Australia Pty Ltd · collab
RandomizedSequentialDouble-blindTreatment
Summary
This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ADX-850 in participants with hypertension.
Timeline
- Start
- 2024-03-21
- Primary completion
- 2026-07-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QPI-1007 | Small interfering RNA (siRNA) | — | — |